Greenwald, Maria <br/><br/>
A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis.  [electronic resource] 

 -  Arthritis research & therapy  Aug 2014 
 - 415 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1478-6362 
<br/><br/><label>Standard No.: </label>10.1186/s13075-014-0415-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Intravenous<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Arthritis, Rheumatoid--drug therapy<br/>B-Cell Activating Factor--immunology<br/>B-Lymphocytes--drug effects<br/>Dose-Response Relationship, Drug<br/>Female<br/>Humans<br/>Injections, Subcutaneous<br/>Male<br/>Middle Aged